Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Doug Turnbull

PharmaDeviceNews Doug Turnbull

Infographic showing Pretzel Therapeutics receiving UK clinical trial authorisation for PX578, featuring mitochondrial research imagery and highlighting planned Phase 2 testing in POLG disease before the end of 2026.

Pharma & Biotech

Pretzel Therapeutics receives UK trial authorisation for PX578 ahead of Phase 2 POLG disease study

by Pallavi Madhiraju
October 31, 2026
0 Comments

Pretzel Therapeutics gains UK trial authorisation for PX578, paving the way for Phase 2 testing in POLG disease before year-end 2026.

Read More

Latest news and features

Pretzel Therapeutics receives UK trial authorisation for PX578 ahead of Phase 2 POLG disease study
Immunome’s varegacestat cut progression risk by 84%, but can it challenge an already approved European desmoid tumour treatment?
Eurosets unveils Trilly Baby oxygenator for infant heart surgery ahead of planned European rollout
Darwin Biotech reports early ALS functional and NfL signals from randomised Phase 1 ALT001 study
Gemelli Biotech highlights 85-patient study linking intestinal sulfide overproduction to distinct gene-expression changes
Avenzo Therapeutics to present first ORION-1 Phase 1 data for selective CDK4 inhibitor AVZO-023
SetPoint Medical completes first Boston implant of FDA-approved rheumatoid arthritis neurostimulation system
TransCode Therapeutics has advanced TTX-MC138 into Phase 2a, so why is it exploring a sale or strategic partnership?
Can Ascletis ASC30 compete with established oral GLP-1 treatments?
Preservative-free ketamine gets FDA approval as NRx Pharmaceuticals targets US hospital supply
Sabirnetug trial failure forces Acumen Pharmaceuticals to reassess Alzheimer’s drug development strategy
Edison Scientific signs Pfizer agreement to deploy Kosmos AI scientist across pharmaceutical R&D

POPULAR NEWS

plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.

Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

August 19, 2026

Pharma & Biotech

Omabit raises $2m to connect fragmented clinical evidence, but can AI improve drug development decisions?

October 27, 2026

Medical Devices & Diagnostics

Presage Technologies SmartSpectra cleared for contactless vital signs monitoring

July 8, 2026

Latest business and industry news

PAG to acquire 51% of Evergrande Property Services for HK$4bn in liquidation-linked sale
Andy Burnham opens door to UK slavery apology but rejects financial reparations
IndiGrid commissions 500 MWh Rajasthan battery project with over Rs 71cr annual revenue potential
US judge blocks Trump administration from threatening election workers before midterms
Adani Energy Solutions gets CCI approval for Rs 3,050cr IntelliSmart deal, but Rs 5,500cr rollout bill looms

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.